These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 24911240)
21. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model. Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874 [TBL] [Abstract][Full Text] [Related]
22. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. Dewan MZ; Terashima K; Taruishi M; Hasegawa H; Ito M; Tanaka Y; Mori N; Sata T; Koyanagi Y; Maeda M; Kubuki Y; Okayama A; Fujii M; Yamamoto N J Virol; 2003 May; 77(9):5286-94. PubMed ID: 12692230 [TBL] [Abstract][Full Text] [Related]
23. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
24. Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor. Tezuka K; Okuma K; Kuramitsu M; Matsuoka S; Tanaka R; Tanaka Y; Hamaguchi I J Virol; 2018 Feb; 92(4):. PubMed ID: 29212930 [TBL] [Abstract][Full Text] [Related]
25. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related]
26. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554 [TBL] [Abstract][Full Text] [Related]
27. The MyD88 pathway in plasmacytoid and CD4+ dendritic cells primarily triggers type I IFN production against measles virus in a mouse infection model. Takaki H; Takeda M; Tahara M; Shingai M; Oshiumi H; Matsumoto M; Seya T J Immunol; 2013 Nov; 191(9):4740-7. PubMed ID: 24078691 [TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299 [TBL] [Abstract][Full Text] [Related]
29. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. Kinpara S; Hasegawa A; Utsunomiya A; Nishitsuji H; Furukawa H; Masuda T; Kannagi M J Virol; 2009 May; 83(10):5101-8. PubMed ID: 19264779 [TBL] [Abstract][Full Text] [Related]
30. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms. Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946 [TBL] [Abstract][Full Text] [Related]
31. [New treatment strategy for adult T-cell leukemia targeting for anti-tumor immunity and a longevity gene-encoded protein]. Kozako T Yakugaku Zasshi; 2011; 131(7):1061-72. PubMed ID: 21720136 [TBL] [Abstract][Full Text] [Related]
32. Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. Houssein M; Fatfat M; Habli Z; Ghazal N; Moodad S; Khalife H; Khalil M; Gali-Muhtasib H Life Sci; 2020 Jun; 251():117639. PubMed ID: 32272181 [TBL] [Abstract][Full Text] [Related]
33. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia. Kawamura K; Tanaka Y; Nakasone H; Ishihara Y; Kako S; Kobayashi S; Tanaka Y; Ohmori T; Uchimaru K; Okamoto S; Mineno J; Shiku H; Nishimura S; Kanda Y Biol Blood Marrow Transplant; 2020 Aug; 26(8):1377-1385. PubMed ID: 32311478 [TBL] [Abstract][Full Text] [Related]
34. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926 [TBL] [Abstract][Full Text] [Related]
35. Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Zimmerman B; Niewiesk S; Lairmore MD Vet Pathol; 2010 Jul; 47(4):677-89. PubMed ID: 20442421 [TBL] [Abstract][Full Text] [Related]
36. Antiviral and antiproliferative activities of recombinant human interferon alpha 2, beta and gamma on HTLV-I and ATL cells in vitro. Koyama Y; Tanaka Y; Oda S; Yamashita U; Eto S J UOEH; 1990 Jun; 12(2):149-61. PubMed ID: 2117774 [TBL] [Abstract][Full Text] [Related]
37. Measles to the Rescue: A Review of Oncolytic Measles Virus. Aref S; Bailey K; Fielding A Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084 [TBL] [Abstract][Full Text] [Related]
38. Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent. Aikawa A; Kozako T; Uchida Y; Yoshimitsu M; Ishitsuka K; Ohsugi T; Honda SI FEBS J; 2020 Sep; 287(18):4005-4015. PubMed ID: 32027454 [TBL] [Abstract][Full Text] [Related]
39. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280 [TBL] [Abstract][Full Text] [Related]
40. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]